Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer

2020 Year in Review - Biosimilars —January 25, 2021

Categories:

Biosimilars

Population-based study results support the use of the neoadjuvant chemotherapy + pertuzumab + trastuzumab biosimilar SB3 treatment regimen in the real-world setting, with responses comparable with those achieved in clinical trials.

A randomized phase 3 trial demonstrated the similarity of the trastuzumab biosimilar SB3 to its reference trastuzumab plus neoadjuvant chemotherapy in terms of pathologic complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive, early or locally advanced breast cancer.1 To evaluate the efficacy of the combination of neoadjuvant chemotherapy with pertuzumab + SB3, an investigator-initiated study was conducted by the Danish Breast Cancer Group (DBCG) in patients with HER2-positive, early breast cancer in the real-world setting2; the results of this study were reported at the American Society of Clinical Oncology 2020 Annual Meeting.

Consecutive patients in the DBCG database were identified who were diagnosed with unilateral early, HER2-positive breast cancer and treated with neoadjuvant chemotherapy in combination with pertuzumab + SB3 from September 1, 2018, to August 31, 2019.2 The primary outcome measure was pCR, which was defined as absence of residual invasive tumor in the breast and axillary lymph nodes.2

A total of 215 patients were identified who received neoadjuvant chemotherapy + pertuzumab + SB3.2 In the study cohort, the median age was 54.8 years (range, 24-81 years); neoadjuvant chemotherapy predominantly consisted of cyclophosphamide + epirubicin followed by paclitaxel, or other chemotherapy followed by paclitaxel.2

Overall, 68% of patients with node-positive disease prior to receiving the neoadjuvant chemotherapy + pertuzumab + SB3 treatment regimen achieved node-negative status after completing the regimen.2 Following the neoadjuvant combination treatment regimen, 56% of patients achieved a pCR. Correlative analyses by demographic and pre-neoadjuvant chemotherapy pathoanatomical factors showed that pCR was significantly related to low estrogen receptor status and high malignancy grade but not to clinical nodal status and tumor size. A trend toward a correlation was seen between pCR rate and small tumor size (pre-neoadjuvant chemotherapy) and high HER2/Cep17 ratio.2

The findings from this population-based study indicate that the neoadjuvant chemotherapy + pertuzumab + SB3 treatment regimen may yield a pCR rate in the real-world setting that is comparable with those previously reported from clinical trials.3

References
1. Pivot X, et al. J Clin Oncol. 2018;36:968-974.
2. Andersson M, et al. ASCO 2020. Abstract 577.
3. Chen S, et al. BMC Cancer. 2019;19:973.

Related Articles
Establishing Analytical and Clinical Similarity Between HD201 and Trastuzumab
2020 Year in Review - Biosimilars
The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab.
Biosimilars Year in Review Introduction
2020 Year in Review - Biosimilars
Phase 3 Study Comparing SB3 and Reference Trastuzumab in HER2-Positive, Early or Locally Advanced Breast Cancer in the Neoadjuvant Setting: 4-Year Follow-Up
2020 Year in Review - Biosimilars
An ongoing extension study from the phase 3 trial of trastuzumab biosimilar SB3 and trastuzumab reference supports similarity in terms of long-term cardiac safety and survival in patients with HER2-positive, early or locally advanced breast cancer.
Last modified: January 25, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code